The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Related to this article
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
Advertisement
Advertisement
Trending on Urology Times
1
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
2
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
3
Altaviva™ Tibial Implant Is Reshaping UUI Therapy
4
Sri Sivalingam, MD: Suction technology raises the bar for URS
5